Search Results

Stereotaxis announced the first treatment of patients with a newly launched Genesis Robotic Magnetic Navigation system at Intermountain Medical Center, flagship hospital of Intermountain Health, based in Salt Lake City.

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has completed the acquisition from Intermountain Health of select assets from its Intermountain Precision Genomics (IPG) laboratory business, including the Precise™ Tumor Test, the Precise Liquid Test, and IPG’s CLIA-certified laboratory in St. George, Utah.

Fabric Genomics is announcing a new partnership with Intermountain Children’s Health to analyze the whole genomes of children sequenced by the Broad Clinical Labs to help speed diagnosis of kids who may have genetic diseases.

Myriad Genetics, Inc. announced it has entered into a definitive agreement to acquire select assets from Intermountain Precision Genomics’ laboratory business, including the Precise™ Tumor Test, the Precise Liquid Test, and IPG’s CLIA-certified laboratory in St. George, Utah where the Precise Tumor Test is currently performed.

Myriad Genetics, Inc., a leader in genetic testing and precision medicine, and Intermountain Precision Genomics, part of the Intermountain Health system, will begin providing oncology test results that allow access to the ComboMATCH trials.

Myriad Genetics, Inc., a leader in genetic testing and precision medicine, and Intermountain Precision Genomics, a service of Intermountain Health, are now certified to offer solid tumor testing to patients in all 50 U.S. states after receiving the New York State Clinical Laboratory Permit.

Health-focused nonprofits like the Drug Information Association (DIA) serve as crucial bridge-builders in the healthcare ecosystem during a time of uncertainty.

GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, and Intermountain Healthcare announced that Galleri®, GRAIL’s groundbreaking multi-cancer early detection blood test, will be offered as a complement to existing single cancer screenings to help advance the delivery of cancer care through early detection.

Myriad Genetics, Inc. announced the expansion of its strategic partnership with Intermountain Precision Genomics, a service of Intermountain Healthcare, to add a new liquid biopsy therapy selection test to its growing oncology portfolio.

Intermountain Forensics, experts in cold case DNA analysis, announced the addition of a dedicated satellite lab for forensic genetic genealogy with new partner Astrea Forensics.